BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
4/8 — Partial
Priority Review
TIVDAK (tisotumab vedotin) by Pfizer. Approved for cervical cancer. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIVDAK (tisotumab vedotin) is an antibody-drug conjugate (ADC) that targets tissue factor (TF), a protein expressed on solid tumors. It is approved for cervical cancer and under investigation across 13 indications including ovarian, endometrial, bladder, esophageal, head and neck, prostate, lung, pancreatic, and colorectal cancers. The mechanism combines antibody-mediated targeting with cytotoxic vedotin payload delivery.
$0.704MPart D
PeakEarly-stage commercial trajectory post-approval with modest Part D spending; brand team focused on indication expansion and market penetration in niche oncology segments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (11)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Started May 2025
100 enrolled
Cervical Cancer
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Started Jun 2023
19 enrolled
Solid Malignancies
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Started Feb 2021
502 enrolled
Cervical Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Started Mar 2019
98 enrolled
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Started Feb 2019
23 enrolled
Solid Tumor
Worked on TIVDAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.